van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. Br Med J 2010;341:c3369.CrossrefWeb of ScienceGoogle Scholar
Degraeuwe PL, Beld MP, Ashorn M, Canani RB, Day AS, Diamanti A, et al. Faecal calprotectin in suspected paediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2015;60: 339–46.Web of ScienceCrossrefPubMedGoogle Scholar
Van de Vijver E, Schreuder AB, Cnossen WR, Muller Kobold AC, van Rheenen PF. Safely ruling out inflammatory bowel disease in children and teenagers without referral for endoscopy. Arch Dis Child 2012;97:1014–8.Web of ScienceCrossrefPubMedGoogle Scholar
Heida A, Holtman GA, Lisman-Van Leeuwen Y, Berger MY, Van Rheenen PF. Avoid endoscopy in children with suspected inflammatory bowel disease who have normal calprotectin levels. J Pediatr Gastroenterol Nutr 2016;62:47–9.PubMedCrossrefWeb of ScienceGoogle Scholar
Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut 2009;58:859–68.CrossrefPubMedWeb of ScienceGoogle Scholar
Sidler MA, Leach ST, Day AS. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis 2008;14:359–66.Web of ScienceCrossrefPubMedGoogle Scholar
Foell D, Wittkowski H, Ren Z, Turton J, Pang G, Daebritz J, et al. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J Pathol 2008:183–92.PubMedWeb of ScienceGoogle Scholar
Lasson A, Stotzer P-O, Ohman L, Isaksson S, Sapnara M, Strid H. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohn’s Colitis 2015;9:26–32.Google Scholar
Olafsdottir E, Aksnes L, Fluge G, Berstad A. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr 2002;91:45–50.CrossrefPubMedGoogle Scholar
Hestvik E, Tumwine JK, Tylleskar T, Grahnquist L, Ndeezi G, Kaddu-Mulindwa DH, et al. Faecal calprotectin concentrations in apparently healthy children aged 0–12 years in urban Kampala, Uganda: a community-based survey. BMC Pediatr 2011;11:9.CrossrefWeb of SciencePubMedGoogle Scholar
Fagerberg UL, Lööf L, Merzoug RD, Hansson L-O, Finkel Y. Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr 2003;37:468–72.CrossrefPubMedGoogle Scholar
Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014;58:795–806.Web of ScienceGoogle Scholar
CLSI. Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline, 3rd ed. CLSI document C28-A3c. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.Google Scholar
Nylund CM, D’Mello S, Kim M-O, Bonkowski E, Däbritz J, Foell D, et al. Granulocyte macrophage-colony-stimulating factor autoantibodies and increased intestinal permeability in Crohn disease. J Pediatr Gastroenterol Nutr 2011;52:542–8.PubMedCrossrefWeb of ScienceGoogle Scholar
Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 2003;52:847–53.CrossrefPubMedGoogle Scholar
Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW, Rueffer A, et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007;56:1706–13.Web of ScienceCrossrefPubMedGoogle Scholar
About the article
Published Online: 2017-07-14
Published in Print: 2017-11-27
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: This study was supported by CisBio Bioassay, Codolet, France (developer and producer of Inflamark®). Trial registry: Clinical trials.gov NCT02588222.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.